As of today, three other GLP-1 receptor agonists remain on the FDA's shortage list: semaglutide (Ozempic, Wegovy), ...

Lawsuits filed in New Jersey are part of hundreds of complaints against UnitedHealthcare, PBMs, and pharmaceutical giants ...

The U.S. Food and Drug Administration on Thursday found that there was no longer a shortage of Eli Lilly's blockbuster weight ...

Eli Lilly & Co.’s weight-loss and diabetes drugs Mounjaro and Zepbound are no longer in short supply in the US, which means ...

Memory-chip maker swung to a profit and posted higher revenue in its fiscal first quarter, though shares fell after the company's outlook missed estimates. CVS ignored substantial evidence from ...

The Food and Drug Administration on Thursday reaffirmed its assessment that Mounjaro and Zepbound, popular drugs for diabetes and obesity ... Hers Health fell by about 10% in Thursday trading on news ...

The Food and Drug Administration (FDA) announced in a statement Tuesday that it has sent warning letters to companies selling ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...

Researchers have achieved impressive results in animal studies with a new weight-loss drug that has no GLP-1-style side ...

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...

Novo Nordisk made a submission to the U.S. Food and Drug Administration (FDA) nominating Novo Nordisk’s semaglutide ...

2024 was one of the most eventful years for the pharmaceutical, biotech, life sciences and medical marketing industries.